Quotes 5-day view Delayed Nasdaq
03/01/2021
03/02/2021
03/03/2021
03/04/2021
03/05/2021
Date
64.66(c)
62.92(c)
61.36(c)
58.7(c)
61.04(c)
Last
1 061 462
562 114
614 029
664 229
643 029
Volume
-9.94% -2.69% -2.48% -4.34% +3.99% Change
Sales 2021
136 M - -
Net income 2021
-204 M - -
Net cash position 2021
1 757 M - -
P/E ratio 2021
-35,9x
Yield 2021
-
Sales 2022
96,6 M - -
Net income 2022
-270 M - -
Net cash position 2022
1 300 M - -
P/E ratio 2022
-27,4x
Yield 2022
-
Capitalization
7 385 M 7 385 M -
EV / Sales 2021
41,3x
EV / Sales 2022
63,0x
Nbr of Employees
291
Free-Float
81,7%
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes...
Notations Surperformance© of Denali Therapeutics Inc.
Trading Rating : Investor Rating :
All news about DENALI THERAPEUTICS INC.
News in other languages on DENALI THERAPEUTICS INC.
- No features available -
Analyst Recommendations on DENALI THERAPEUTICS INC.
Chart DENALI THERAPEUTICS INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends DENALI THERAPEUTICS INC.
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
11
Average target price
90,67 $
Last Close Price
61,04 $
Spread / Highest target
73,7%
Spread / Average Target
48,5%
Spread / Lowest Target
-1,70%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
